AVI BioPharma, Inc. (AVII) Announces Publication Of West Nile And Dengue Virus NEUGENE Antisense Studies In The Journal of Virology
10/19/2005 5:13:10 PM
PORTLAND, Ore.--(BUSINESS WIRE)--March 30, 2005--AVI BioPharma, Inc. (Nasdaq:AVII), today announced the publication of two articles describing preclinical studies in which its NEUGENE(R) antisense drugs were used to inhibit dengue virus and West Nile virus (WNV) infection. The two articles were published in the April 2005 Journal of Virology, and are available online at http://jvi.asm.org/current.shtml.
"These studies are an important scientific validation of our antiviral program efforts," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "Our ongoing research using NEUGENE antisense technology to inhibit viral infection represents an exciting potential alternative to current antiviral drugs."